Intellia Therapeutics (NTLA) Q4 2025 earnings review
Cost Discipline Shines While Nex-z Cloud Hangs
Intellia closed 2025 with significant expense reductions, driving Q4 net loss down 26% YoY to $95.8M. Operating leverage is clearly materializing, with R&D expenses dropping 24% YoY. This financial discipline has extended the cash runway into the second half of 2027, successfully bridging the company past the anticipated lonvo-z launch. However, a major overhang remains: while the FDA lifted the clinical hold on the smaller nex-z ATTRv-PN trial, the hold on the critical ATTR-CM Phase 3 trial remains unresolved following a Q3 patient death. This shifts the immediate commercial burden entirely onto the lonvo-z HAE program.
🐂 Bull Case
The Phase 3 HAELO trial for lonvo-z completed dosing in September 2025. With topline data expected mid-2026 and a 99% patient willingness-to-take metric from market research, the path to a H1 2027 commercial launch is highly visible and well-funded.
The Q1 2025 restructuring (which included a 27% workforce reduction) continues to pay off. Q4 total operating expenses fell 18% YoY to $121.7M, successfully stabilizing the cash burn rate.
🐻 Bear Case
The FDA clinical hold on the MAGNITUDE (ATTR-CM) trial remains active. This is Intellia's largest addressable market, and prolonged delays allow competitors like Alnylam to further entrench their standard-of-care positioning.
With the nex-z program facing regulatory headwinds, Intellia's near-term valuation is almost entirely dependent on a flawless execution of the lonvo-z HAE launch in a competitive market.
⚖️ Verdict: ⚪
Neutral. Management is executing flawlessly on what they can control (costs, lonvo-z milestones), but the unresolved ATTR-CM clinical hold limits upside. The extended cash runway is a strong positive, giving the company time to navigate the FDA negotiations.
Key Themes
Nex-z ATTR-CM Clinical Hold Persists
Management touted 2025 as a time of accomplishment, but this narrative is contradicted by the persistent regulatory roadblock on their largest asset. Following a patient death in Q3, the FDA placed holds on both nex-z Phase 3 trials. While the smaller MAGNITUDE-2 (ATTRv-PN) hold was lifted in January 2026, the MAGNITUDE (ATTR-CM) hold remains active. The company noted 'engagement with FDA is ongoing,' but provided no timeline, making this a critical monitoring point for the ATTR franchise valuation.
Lonvo-z Clinical and Commercial Execution
The HAE program is stable and progressing exactly as guided. Dosing for the 80-patient HAELO Phase 3 trial completed in September 2025. The company is actively pivoting to commercial readiness: expanding field medical teams, engaging payers, and preparing for a BLA submission in H2 2026. This CRISPR-based in vivo therapy targets the KLKB1 gene and aims for a 'functional cure' (zero attacks off chronic therapy), a highly differentiated profile.
OpEx Deceleration Secures Cash Runway
R&D expenses are decelerating rapidly, dropping from $116.9M in 24Q4 to $88.7M in 25Q4. Total operating expenses fell from $149.3M to $121.7M over the same period. This sharp contraction—driven by the early 2025 restructuring, workforce reduction, and trial enrollment completions—has officially extended the cash runway from 'mid-2027' to 'second half of 2027', entirely funding the anticipated lonvo-z launch.
MAGNITUDE-2 Regulatory Win
A notable positive development was the FDA lifting the clinical hold on the MAGNITUDE-2 trial (ATTRv-PN) on January 27, 2026. Resuming enrollment here partially de-risks the in vivo CRISPR TTR-knockdown platform, suggesting the FDA may view the Q3 patient death as isolated to the specific cardiomyopathy cohort or patient comorbidities rather than a systemic platform flaw.
Macro Pricing Environment for Gene Therapies
As the company shifts toward a 2027 commercial launch for lonvo-z, payer acceptance of high-cost, one-time gene therapies remains a macro concern. Management previously noted they would not set 'new records for high-priced drugs', but navigating pharmacy benefit managers (PBMs) and securing broad reimbursement in a cost-constrained, potentially tariff-heavy U.S. pharmaceutical landscape carries high execution risk.
SparingVision Collaboration Terminated
Collaboration revenue spiked 79% YoY to $23.0M in Q4, but this was a low-quality beat. $9.0M of this revenue was recognized due to the termination of the license and collaboration agreement with SparingVision SAS. This termination quietly removes a partnered ocular program from Intellia's broader pipeline, further concentrating the company's reliance on its liver-directed (nex-z and lonvo-z) assets.
Other KPIs
Decelerating burn rate. Cash decreased by $64.8 million sequentially from Q3 2025 ($669.9M). The total cash balance is down from $861.7M at the end of 2024, but the burn rate has slowed significantly due to the $115M ATM raise in Q3 and aggressive OpEx cuts, leaving a robust balance sheet.
Accelerating significantly from $12.9M in 24Q4. However, this is largely a one-time accounting recognition ($9.0M) related to the SparingVision termination, coupled with an increase in cost reimbursements from the core Regeneron partnership.
Guidance
Accelerating/Improving. This is an upgrade from the prior 'mid-2027' guidance. Management explicitly confirmed this runway is sufficient to fund operations through the anticipated U.S. commercial launch of lonvo-z for HAE.
Stable. The company remains on track to report pivotal Phase 3 data in mid-2026, which is the primary catalyst for the stock over the next 12 months.
Stable. If the HAELO data is supportive, the company is targeting a BLA submission in H2 2026, setting up a potential FDA approval and commercial launch in H1 2027.
Key Questions
FDA Requirements for ATTR-CM
With the MAGNITUDE-2 hold lifted, what specific additional data or protocol amendments is the FDA requiring to lift the hold on the larger MAGNITUDE ATTR-CM trial?
Commercial Buildout Costs
R&D and G&A expenses have declined steadily throughout 2025. As you build out the field sales and reimbursement teams in 2026 for the lonvo-z launch, should we expect a reversal and re-acceleration in G&A spending?
Impact of MAGNITUDE Delays
Prior to the hold, MAGNITUDE was expected to enroll over 650 patients by the end of 2025. How significantly has this clinical pause pushed back the expected completion of enrollment and subsequent data readouts?
Pipeline Strategy Post-SparingVision
With the termination of the SparingVision ocular agreement, what is the strategy for monetizing or advancing pipeline assets outside of the core liver-directed indications?